Zerlasiran (SLN360)
Elevated Lipoprotein(a) for Cardiovascular Risk Reduction
Phase 2Active
Key Facts
Indication
Elevated Lipoprotein(a) for Cardiovascular Risk Reduction
Phase
Phase 2
Status
Active
Company
About Silence Therapeutics
Silence Therapeutics is a UK-based pioneer in RNA interference (RNAi) therapeutics, utilizing its proprietary mRNAi GOLD™ platform to design targeted siRNA medicines. The company has validated its technology through significant partnerships with AstraZeneca and Hansoh Pharma, while advancing its internal lead asset, zerlasiran (SLN360), for cardiovascular disease. Its strategy balances internal pipeline development in cardiometabolic and hematologic diseases with platform licensing, aiming to create a sustainable biotech with multiple value inflection points.
View full company profileTherapeutic Areas
Other Elevated Lipoprotein(a) for Cardiovascular Risk Reduction Drugs
| Drug | Company | Phase |
|---|---|---|
| Olpasiran (AMG 890) | Amgen | Phase 3 |